1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
Recursion(RXRX) The Motley Fool·2024-07-13 21:29
This biotech is on the verge of a groundbreaking innovation, but it might not get over the hump.Recursion Pharmaceuticals (RXRX 8.85%) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development. Recursion Pharmaceuticals remains a small and little-known player in the industry, and like all clinical-stage biotechs, the stock is relatively risky. Ther ...